A5018422639- Anesthesia and Sedative Agents
- Acute Ischemic Stroke Management
- Intracerebral and Subarachnoid Hemorrhage Research
- Healthcare Systems and Practices
- Anesthesia and Pain Management
- Anesthesia and Neurotoxicity Research
- Traumatic Brain Injury and Neurovascular Disturbances
- Intensive Care Unit Cognitive Disorders
- Orthopedic Infections and Treatments
- Bacterial Infections and Vaccines
- Stroke Rehabilitation and Recovery
- Surgical site infection prevention
- Palliative Care and End-of-Life Issues
- Cerebrospinal fluid and hydrocephalus
- Pneumonia and Respiratory Infections
- Adrenal Hormones and Disorders
- Antibiotics Pharmacokinetics and Efficacy
- Inflammatory mediators and NSAID effects
- Pharmaceutical Practices and Patient Outcomes
- Neuroscience and Neuropharmacology Research
- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
- Healthcare cost, quality, practices
- Atrial Fibrillation Management and Outcomes
- Disaster Response and Management
Cumberland Pharmaceuticals (United States)
2025
University Hospitals of Cleveland
2018-2022
Case Western Reserve University
2012-2021
University School
2020-2021
Neurological Surgery
2020
Kyowa Hakko Kirin (Singapore)
2016
University Hospitals Cleveland Medical Center
2010-2014
Abstract Background Telavancin (TLV) is a lipoglycopeptide approved for the treatment of complicated skin and structure infection (cSSSI) hospital acquired ventilator associated bacterial pneumonia caused by susceptible Gram-positive bacteria. Data lacking published outcomes in OPAT. This study evaluated use TLV patients receiving Methods Medical records adult who received during 2021-2023 OPAT were queried. Demographics, diagnosis, therapy characteristics, laboratory microbiologic data,...
Intravenous non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in healthcare settings, but their comparative safety and resource utilization impacts remain understudied. This study aimed to compare adverse drug reactions (ADRs) (HCRU) between patients receiving IV-ibuprofen versus IV/IM ketorolac. A retrospective, longitudinal analysis was conducted using an all-payer database, examining records from January 1, 2014, June 3, 2023. The included both adult (≥18 years) pediatric...
Prior to the approval of andexanet, there were no FDA-approved reversal agents indicated for treatment factor Xa inhibitor (FXaI) associated major bleed. Four-factor prothrombin complex concentrate (4F-PCC) has been widely used off-label FXaI-associated bleeding. The purpose this study was compare effectiveness and safety andexanet 4F-PCC intracranial haemorrhage. primary end point is in-hospital mortality; secondary endpoints include haemostatic efficacy safety. This a singlecentre,...
Traeger, Jessica; Makii, Jason; Bush, Weston; Popa, Andreea; Immler, Ellen; Honda, Yumi; Pesa, Nicholas Author Information
Stroke patients need written information on how to recognize and prevent a secondary stroke. Limited health literacy is associated with medication errors lack of knowledge for chronic conditions. Written communication needs be inviting understood by the largest population possible. At University Hospitals Comprehensive Cerebrovascular Center (UHCSCC) education book, “HOPE, A Recovery Guide” from National Association has been given many years. It 66 pages long, black white print very few...
Traeger, Jessica; Makii, Jason; Ostergard, Thomas; Barcelona, Robert; Schmaier, Alvin Author Information
Critical Care Medicine: January 2020 - Volume 48 Issue 1 p 476 doi: 10.1097/01.ccm.0000642912.64809.c7
Popa, Andreea1; Hoffman, Brian1; Wang, Nan1; Schmotzer, Christine1; Lemonovich, Tracy1; Armitage, Keith2; Traeger, Jessica1; Makii, Jason1 Author Information
Hoffman, Brian1; Barcelona, Robert1; Bush, Weston1; Ginwalla, Mahazarin1; Makii, Jason1 Author Information
Objective: To evaluate the current impact of tPA cost on inpatient reimbursement at a large, integrated health system stroke care. Background: In 2016, University Hospitals System Stroke Program initiated high reliability medicine initiative to improve value care by optimizing quality and reducing cost. That year, Kleindorfer et al reported relative increase in alteplase (tPA) outpaced Medicare reimbursement. Since then, FDA physician’s labelling rule national guideline updates have expanded...
Shuler, Evan1; Tumbush, Courtney1; Makii, Jason1; Bixby, Alex2; Hojat, Leila1 Author Information
Makii, Jason; Kloos, Janet; Popovich, Kehllee; Dzigiel, Michael; Kubec, stephanie; Snyder, Robert; Korosec, Elisabeth; Hewett, Elizabeth Author Information
Popovich, Kehllee; Kloos, Janet; Makii, Jason; Korosec, Elisabeth; Hewett, Elizabeth; Dzigiel, Michael; Kubec, stephanie; Snyder, Robert Author Information